Invention Grant
US09309242B2 Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
有权
取代的吡啶并[2,3-b]吡嗪作为FGFR激酶抑制剂
![Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors](/docs/US/2016-04-12/US09309242B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
- Patent Title (中): 取代的吡啶并[2,3-b]吡嗪作为FGFR激酶抑制剂
-
Application No.: US14354832Application Date: 2012-10-26
-
Publication No.: US09309242B2Publication Date: 2016-04-12
- Inventor: Valerio Berdini , Gordon Saxty , Patrick Rene Angibaud , Olivier Alexis Georges Querolle , Virginie Sophie Poncelet , Bruno Roux , Lieven Meerpoel
- Applicant: ASTEX THERAPEUTICS LIMITED
- Applicant Address: GB Cambridge
- Assignee: ASTEX THERAPEUTICS LTD
- Current Assignee: ASTEX THERAPEUTICS LTD
- Current Assignee Address: GB Cambridge
- Agency: Heslin Rothenberg Farley & Mesiti P.C.
- Priority: GB1118656.6 20111028
- International Application: PCT/GB2012/052672 WO 20121026
- International Announcement: WO2013/061080 WO 20130502
- Main IPC: A61K31/4985
- IPC: A61K31/4985 ; C07D241/36 ; C07D471/04 ; A61K31/506 ; A61K31/5377
![Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors](/abs-image/US/2016/04/12/US09309242B2/abs.jpg.150x150.jpg)
Abstract:
The invention relates to new pyridopyrazine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
Public/Granted literature
- US20140288053A1 ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES Public/Granted day:2014-09-25
Information query
IPC分类:
